Opinion|Videos|September 3, 2024
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
Medical experts discuss the data gathered from the ASCERTAIN trial.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Although oral decitabine-cedazuridine has been FDA approved for some time, the ASCERTAIN trial data are a recent advancement in our knowledge of this drug and its use in myelodysplastic syndromes (MDS). Briefly describe the ASCERTAIN trial design.
- What are some key takeaways regarding the outcomes of treating MDS with oral decitabine-cedazuridine compared with intravenous decitabine, according to the ASCERTAIN data?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
Physical Function Views Differ Between Older AML Patients, Clinicians
3
Evolocumab Cuts Death Risk for a First Heart Attack or Stroke
4
Better Cardiovascular Health Tied to Lower Overactive Bladder Risk
5